Artiva Biotherapeutics (ARTV) Liabilities and Shareholders Equity (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $106.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 44.6% year-over-year to $106.0 million; the TTM figure through Mar 2026 stood at $555.1 million (down 20.96% YoY), while the FY2025 annual figure was $130.9 million, down 37.52% from the prior year.
• Liabilities and Shareholders Equity retreated to $106.0 million in Q1 2026 per ARTV's latest filing, from $130.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $225.6 million in Q3 2024 and bottomed at $75.9 million in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $151.4 million across 4 years, with a median of $148.9 million in 2025.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity jumped 123.14% — and 2026, when it slumped 44.6%.
• Artiva Biotherapeutics' Liabilities and Shareholders Equity stood at $105.1 million in 2023, then jumped by 99.38% to $209.6 million in 2024, then sank by 37.52% to $130.9 million in 2025, then decreased by 19.08% to $106.0 million in 2026.
• Business Quant data shows ARTV's Liabilities and Shareholders Equity at $106.0 million in Q1 2026, $130.9 million in Q4 2025, and $148.9 million in Q3 2025.